Latest News

A 3-patient case series explored photothermal biomodulated PRP with laser and LED therapy for acne-related erythema, hyperpigmentation, and scarring.

Fractional carbon dioxide laser targets acne conglobata skin bridges and sinus tracts, delivering marked improvement, quick healing, and no recurrence.

Advanced practice providers will gather September 12 for a full-day program covering skin cancer prevention, diagnosis, staging, treatment, and procedural skills.

This review of the latest dermatological studies includes insights on AGA and cardiovascular risk, adverse events associated with cutaneous procedures, narrowband-UVB phototherapy for urticaria pigmentosa, and more.

Robert R. Redfield, MD, will help guide development of GX-03 as Turn Therapeutics advances its phase 2 atopic dermatitis program.

Post hoc RESOLVE analysis shows that patients weighing at least 100 kg experience slower clinical response rates to brodalumab than those under 100 kg, establishing body weight over BMI as a key predictor of treatment timing.

Study tracks teens on isotretinoin, finding stable cognition but modest rises in depression and anxiety symptoms, reinforcing the need for ongoing mental health monitoring.

FDA granted QRX003 RPD designation for PSS, adding to its Netherton syndrome designation as Quoin prepares for a phase 2 study.

Real-world cohort research links psoriasis biologics to notably fewer heart attacks and strokes over 10 years, with benefits across drug classes and races.

Are "clean" skin care routines legitimate, or are they just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.

Clinicians can bridge the gap between online trends and evidence-based outcomes by leveraging patient curiosity, emphasizing ingredient transparency, and delivering personalized in-office care.

AbbVie completed its $10.9 billion Apogee acquisition, adding IL-13 antibody zumilokibart and other inflammatory disease assets.

This review of the latest dermatological studies includes insights on adalimumab durability in HS, medicolegal issues in hair transplantation, yellow light and vitamin C for melasma, and more.